Schedule an Appointment

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Aquila Diagnostic Systems Inc.

Location: Edmonton, Alberta

Sector: Life Science

.

Add to Shortlist
Express Interest

Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.

Business Documents

MG cp Summary

Low cost technology – Ability to price Aquila products at same price as veterinarians pay today for an inferior product

 

Ability to work with any industry standard diagnostic instrument – Aquila is not building a diagnostic instrument: we are agnostic to instrument providing the customer with a wide variety of instrument options depending upon budget and requirements.

 

Patents on Aquila hydrogelStrong patents in place in a technology where such patents are extremely difficult to achieve

 

Ability to work with “dirty” samples – Aquila’s patented hydrogel provides a significant and sustainable competitive advantage with its unmatched ability to work with “dirty” samples such as milk and feces.

 

Simple or no DNA extraction required from sample – Minimizes or eliminates step when compared to conventional PCR technology. Lowers cost and time to perform test.

“ Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.”

Brent James, CEO, B.Comm UBC; MBA Sloan School MIT

Brent James has a 30-year history of accomplishments in the high tech field including co-founding a company (MDSI) that went public on NASDAQ, and being the turn-around CEO of a company (Abebooks.com), which was sold to Amazon.

 

Dr. Jason Acker, Co-Founder & CTO; BSc, MSc, MBA, PhD

Dr.Jason Acker, Co-Founder and Chief Technology Officer, brings more than 15 years of experience with multinational pharmaceutical and biotechnology companies in Canada, USA, Singapore and the U.K.  Jason also managed interdisciplinary teams at the University of Alberta, Canadian Blood Services, and Harvard Medical School.

 

David Alton, Co-Founder & COO; MBA

David Alton co-Founder and Chief Operating Officer of Aquila, has extensive experience in the micro and nano technology sectors, research management and company start-ups